PeptiMimesis PeptiMimesis

PeptiMimesis is a strategic partner in the design, the discovery and the early development of transmembrane therapeutic peptides. Our innovative approach enables the identification of peptidomimetic candidates interfering with the hetero- and/or the homodimerization of target receptors.

PeptiMimesis will develop its pipeline against key targets in the fields of oncology and immuno-oncology and is open to initiate collaboration with pharma partners on receptors of interest.

Press Releases

16-02-29 PeptiMimesis: New biotech startup

PeptiMimesis: New biotech startup developing next generation therapeutic peptides in immuno-oncology, oncology and immune diseases

16-03-08 Ipsen and PeptiMimesis partnership

Ipsen and PeptiMimesis announce a research partnership in oncology

16-04-20 PeptiMimesis secures €1.2m ($1.4m) from Cap Innov’Est

The company will launch its breakthrough technology-platform dedicated to identifying next-generation therapeutic peptides

17-03-15 PeptiMimesis receives second tranche of seed funding to further advance its transmembrane peptide pipeline

Cap Innov’Est renews its support for the unique approach to HER2 positive breast cancer–derived brain metastasis

850 Boulevard Sébastien Brant
67400 Illkirch, France